within Pharmacolibrary.Drugs.ATC.C;

model C02AB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 0.6666666666666666,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.0013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0028333333333333335,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Methyldopa is a centrally acting alpha-2 adrenergic agonist used primarily as an antihypertensive agent. It is particularly used in the management of hypertension during pregnancy due to its established safety profile. While it is less frequently employed today in the general population due to availability of newer antihypertensives, methyldopa remains a standard in pregnancy-induced hypertension.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers (mixed sex) after single oral dose administration.</p><h4>References</h4><ol><li><p>Huebert, ND, et al., &amp; Haegele, KD (1983). A comparison of the effects of reversible and irreversible inhibitors of aromatic L-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3,4-dihydroxyphenylalanine. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 11(3) 195â€“200. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6135575/&quot;>https://pubmed.ncbi.nlm.nih.gov/6135575</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C02AB02;
